Curio Digital Therapeutics

Curio Digital Therapeutics develops AI-driven digital-first behavioral health solutions specifically for women's mental health across fertility, pregnancy, postpartum, and menopause life stages. The company offers Prescription Digital Therapeutic (PDT) products FDA-authorized for postpartum depression treatment, complemented by coaching and therapist-supported programs. Core offerings include MamaLift and MamaLift Plus, on-demand digital therapy platforms featuring evidence-based cognitive behavioral therapy (CBT) lessons, health trackers, and live health coach support. Curio-I is an AI-powered predictive platform for early identification and risk stratification of mental health disorders affecting women. All products are validated through clinical trials, with seven published studies demonstrating clinical efficacy. The platform operates on cloud-first, mobile-first architecture enabling anytime, anywhere access. Early adopters and partners include Mount Sinai Health System, Columbia University, and various health plans. The company has received recognition from Business Insider, BioNJ, and innovation awards including Point32 and MassChallenge. Product outcomes show 2 of 3 women achieving symptom improvement below depression thresholds, 70% user referral rates, and 5:1 return on investment metrics.